Accès ouvert
2026
article
OpenAlex
Andrew M. Moon, Ted K. Yanagihara, Laura A. Dawson, Jeong Il Yu et autres
PURPOSE: External beam radiation therapy (EBRT) has gained delayed acceptance as a recommended first-line treatment modality for patients with hepatocellular carcinoma (HCC), given limited evidence that it improves overall survival (OS). We analyzed individual patient data (IPD) from an international cohort to …
us, ca, kr, jp, hk, it, au, cn, de, cl, in, ae, nl, es
(code pays fourni par la source)
2026
article
OpenAlex
Etsuko Moriyama, H. Koga, Takashi Niizeki, Hideki Iwamoto et autres
BACKGROUND: Malignant hepatocellular neoplasm, not otherwise specified (HCN, NOS), is a rare primary liver tumor showing overlapping features of hepatoblastoma and hepatocellular carcinoma. Because of its rarity and histopathologic heterogeneity, the optimal treatment strategy for HCN, NOS remains undefined. AIM AND METHODS: …
jp
(code pays fourni par la source)
Accès ouvert
2025
article
OpenAlex
Ryu Sasaki, Shigeo Shimose, Issei Saeki, Takanori Ito et autres
BACKGROUND & AIMS: Despite the advances in systemic therapy for unresectable hepatocellular carcinoma (HCC), patients with Child-Pugh class B (CP-B) liver function face a significant unmet need. This study evaluated the efficacy and safety of atezolizumab plus bevacizumab (Atez/Bev) in patients with …
jp
(code pays fourni par la source)
2025
article
OpenAlex
Federica Lo Prinzi, Federico Rossari, Antonio De Rosa, Caterina Vivaldi et autres
INTRODUCTION: Liver transplantation (LT) indications for hepatocellular carcinoma (HCC) have broadened, increasing the need for systemic therapy in post-transplant recurrence. Because of the risks of graft rejection and uncertain efficacy, immunotherapy remains controversial, making tyrosine kinase inhibitors (TKIs) such as lenvatinib and …
it, jp
(code pays fourni par la source)
Accès ouvert
2025
article
OpenAlex
Takanori Ito, Shigeo Shimose, Issei Saeki, Yasuto Takeuchi et autres
BACKGROUND AND AIM: Data on sequential immune checkpoint inhibitor (ICI) retreatment following initial atezolizumab plus bevacizumab (Atez + Bev) are limited. This study aimed to evaluate the efficacy and safety of sequential ICI retreatment in patients with unresectable hepatocellular carcinoma (uHCC). METHODS: …
jp
(code pays fourni par la source)
Accès ouvert
2025
article
OpenAlex
Shigeo Shimose, Hideki Iwamoto, Takashi Niizeki, Tomotake Shirono et autres
Objective Hepatic encephalopathy (HE) is a serious adverse event associated with lenvatinib (LEN) that requires discontinuation of the medication. We investigated the risk factors for HE in patients with hepatocellular carcinoma (HCC) who received LEN. We also explored the usefulness of rifaximin …
jp
(code pays fourni par la source)
2025
article
OpenAlex
Takeshi Hatanaka, Shigeo Shimose, Takanori Ito, Joji Tani et autres
AIM: This study aimed to evaluate the association between the efficacy of durvalumab plus tremelimumab (Dur/Tre) and metabolic dysfunction-associated steatotic liver disease (MASLD) in patients with hepatocellular carcinoma (HCC). METHODS: A total of 239 patients with HCC who received Dur/Tre between March …
jp
(code pays fourni par la source)
Accès ouvert
2025
article
OpenAlex
Shigeo Shimose, Takashi Niizeki, Hideki Iwamoto, Masatoshi Tanaka et autres
AIM: The efficacy of sequential therapy with lenvatinib and transcatheter arterial chemoembolization (LEN-TACE) has been previously reported. This study aimed to evaluate the efficacy and safety of LEN-TACE compared with TACE in patients with hepatocellular carcinoma (HCC) within the up-to-seven criteria. METHODS: …
jp
(code pays fourni par la source)
Accès ouvert
2025
article
OpenAlex
Shigeo Shimose, Issei Saeki, Takanori Ito, Yasuto Takeuchi et autres
BACKGROUND: This study aimed to investigate the changes in oncological resection status in patients with unresectable hepatocellular carcinoma (u-HCC) receiving atezolizumab plus bevacizumab (Atez/Bev) and the impact of conversion therapy following Atez/Bev treatment. METHODS: This cohort included 631 patients with u-HCC treated …
jp
(code pays fourni par la source)
Accès ouvert
2025
article
OpenAlex
Jaekyung Cheon, Shigeo Shimose, Hyung‐Don Kim, Takashi Niizeki et autres
PURPOSE: Atezolizumab-bevacizumab (AB) is the established first-line systemic therapy for patients with unresectable hepatocellular carcinoma (uHCC). However, the optimal second-line treatment for patients unresponsive to AB remains undefined. PATIENTS AND METHODS: This multicenter, retrospective study included patients with uHCC who underwent second-line …
kr, jp
(code pays fourni par la source)
Accès ouvert
2024
article
OpenAlex
Takanori Ito, Shigeo Shimose, Joji Tani, Tetsu Tomonari et autres
AIM: Durvalumab plus tremelimumab (Dur/Tre) is a first-line systemic treatment option for unresectable hepatocellular carcinoma (uHCC). However, the management of severe immune-mediated adverse events (imAEs) is challenging. Therefore, we investigated the relationship between severe imAEs and antitumor responses in patients with uHCC …
jp
(code pays fourni par la source)
Accès ouvert
2024
article
OpenAlex
Hiroyuki Suzuki, Tomotake Shirono, Reiichiro Kondo, Toshimitsu Tanaka et autres
Hepatic undifferentiated pleomorphic sarcoma (UPS) is a rare malignant mesenchymal tumor with unclear cancer-related genetic mutations. In a 60-year-old Japanese woman with a rapidly growing, inoperable hepatic UPS, a genetic mutation analysis revealed KRAS and TP53 mutations. Despite initiating hepatic arterial infusion …
jp
(code pays fourni par la source)